Giant cell myocarditis

Revision as of 12:01, 5 September 2011 by C Michael Gibson (talk | contribs)
Jump to navigation Jump to search

WikiDoc Resources for Giant cell myocarditis

Articles

Most recent articles on Giant cell myocarditis

Most cited articles on Giant cell myocarditis

Review articles on Giant cell myocarditis

Articles on Giant cell myocarditis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Giant cell myocarditis

Images of Giant cell myocarditis

Photos of Giant cell myocarditis

Podcasts & MP3s on Giant cell myocarditis

Videos on Giant cell myocarditis

Evidence Based Medicine

Cochrane Collaboration on Giant cell myocarditis

Bandolier on Giant cell myocarditis

TRIP on Giant cell myocarditis

Clinical Trials

Ongoing Trials on Giant cell myocarditis at Clinical Trials.gov

Trial results on Giant cell myocarditis

Clinical Trials on Giant cell myocarditis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Giant cell myocarditis

NICE Guidance on Giant cell myocarditis

NHS PRODIGY Guidance

FDA on Giant cell myocarditis

CDC on Giant cell myocarditis

Books

Books on Giant cell myocarditis

News

Giant cell myocarditis in the news

Be alerted to news on Giant cell myocarditis

News trends on Giant cell myocarditis

Commentary

Blogs on Giant cell myocarditis

Definitions

Definitions of Giant cell myocarditis

Patient Resources / Community

Patient resources on Giant cell myocarditis

Discussion groups on Giant cell myocarditis

Patient Handouts on Giant cell myocarditis

Directions to Hospitals Treating Giant cell myocarditis

Risk calculators and risk factors for Giant cell myocarditis

Healthcare Provider Resources

Symptoms of Giant cell myocarditis

Causes & Risk Factors for Giant cell myocarditis

Diagnostic studies for Giant cell myocarditis

Treatment of Giant cell myocarditis

Continuing Medical Education (CME)

CME Programs on Giant cell myocarditis

International

Giant cell myocarditis en Espanol

Giant cell myocarditis en Francais

Business

Giant cell myocarditis in the Marketplace

Patents on Giant cell myocarditis

Experimental / Informatics

List of terms related to Giant cell myocarditis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Giant cell myocarditis (GCM) or Idiopathic Giant cell myocarditis (IGCM) is a rare but often fatal inflammatory process involving the myocardium. Other than cardiac transplantation, there is no known effective treatment for giant cell mycoarditis.

Pathophysiology

because of the unknown nature of the disorder. GCM is usually characterized by progressive congestive heart failure, and is frequently associated with refractory ventricular arrhythmias. The majority of patients die secondary to congestive heart failure, although some have survived for long periods, often after immunosuppressive treatment. [1] [2]

This disease often affects young otherwise healthy individuals. The rate of death or heart transplantation is approximately 70% at one year. Data from a Lewis Rat model and from observational human studies suggest that GCM is mediated by T lymphocytes and may respond to treatment aimed at attenuating T cell function.

Numerous autoimmune disorders have been associated with giant-cell myocarditis in case reports, but no data have been available on the incidence of these disorders in a study population with giant-cell myocarditis.

The Giant Cell Myocarditis Registry is a clinical and pathologic database from 63 cases of giant cell myocarditis gathered from 36 medical centers. Findings from the registry include the following: the sensitivity of endomyocardial biopsy for GCM for patients who undergo transplantation or autopsy is approximately 80%. Registry subjects who received cyclosporine and/or azathioprine, with steroid and sometimes muromonab-CD3 had prolonged transplant-free survival (12.6 months vs 3.0 months for no immunosuppression.[3].

Gross Pathological Findings

Images shown below are courtesy of Professor Peter Anderson DVM PhD and published with permission. © PEIR, University of Alabama at Birmingham, Department of Pathology

Microscopic Pathological Findings

Images shown below are courtesy of Professor Peter Anderson DVM PhD and published with permission. © PEIR, University of Alabama at Birmingham, Department of Pathology

Diffuse geographic myocardial necrosis at low-power magnification. Numerous giant cells (arrows) can be identified within the inflammatory infiltrate (hematoxylin and eosin, x100)
Multinucleated giant cells (long arrows) are seen adjacent to degenerating myocytes (short arrows). The cellular infiltrate contains lymphocytes, histiocytes, and collections of eosinophils (arrowheads) (hematoxylin and eosin, x400)

Natural History, Complications, and Prognosis

Post-transplantation survival is approximately 71% at five years despite a 25% rate of giant cell infiltration in the donor heart.

These findings should be confirmed with a randomized trial of immunosuppression including muromonab-CD3, cyclosporine, and steroids.

Giant cell myocarditis may recur after transplantation but may respond to augmented immunosuppression.

References

  1. Desjardins V, Pelletier G, Leung TK, Waters D. Successful treatment of severe heart failure caused by idiopathic giant cell myocarditis. Can J Cardiol 1992;8:788-92
  2. Ren H, Poston RS Jr, Hruban RH, Baumgartner WA, Baughman KL, Hutchins GM. Long survival with giant cell myocarditis. Mod Pathol 1993;6:402-7.
  3. Cooper LT, Berry GJ, Shabetai R.Idiopathic Giant-Cell Myocarditis — Natural History and Treatment. N Engl J Med. 1997 Jun 26;336(26):1860-6


Template:WikiDoc Sources